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ABSTRACT
Objectives: Facioscapulohumeral muscular dystrophy
type 1 (FSHD1) has been genetically linked to reduced
numbers (≤8) of D4Z4 repeats at 4q35. Particularly
severe FSHD cases, characterised by an infantile onset
and presence of additional extra-muscular features,
have been associated with the shortest D4Z4 reduced
alleles with 1–3 repeats (1–3 DRA). We searched for
signs of perinatal onset and evaluated disease outcome
through the systematic collection of clinical and
anamnestic records of de novo and familial index cases
and their relatives, carrying 1–3 DRA.
Setting: Italy.
Participants: 66 index cases and 33 relatives carrying
1–3 DRA.
Outcomes: The clinical examination was performed
using the standardised FSHD evaluation form with
validated inter-rater reliability. To investigate the earliest
signs of disease, we designed the Infantile Anamnestic
Questionnaire (IAQ). Comparison of age at onset was
performed using the non-parametric Wilcoxon rank-sum
or Kruskal-Wallis test. Comparison of the FSHD score
was performed using a general linear model and Wald
test. Kaplan-Meier survival analysis was used to estimate
the age-specific cumulative motor impairment risk.
Results: No patients had perinatal onset. Among index
cases, 36 (54.5%) showed the first signs by 10 years of
age. The large majority of patients with early disease
onset (26 out of 36, 72.2%) were de novo; whereas the
majority of patients with disease onset after 10 years of
age were familial (16, 53.3%). Comparison of the disease
severity outcome between index cases with age at onset
before and over 10 years of age, failed to detect statistical
significance (Wald test p value=0.064). Of 61 index
cases, only 17 (27.9%) presented extra-muscular
conditions. Relatives carrying 1–3 DRA showed a large
clinical variability ranging from healthy subjects, to
patients with severe motor impairment.
Conclusions: The size of the D4Z4 allele is not always
predictive of severe clinical outcome. The high degree of
clinical variability suggests that additional factors
contribute to the phenotype complexity.
INTRODUCTION
Facioscapulohumeral muscular dystrophy
(FSHD (MIM 158900)) is the third most
common muscular dystrophy with an
Strengths and limitations of this study
▪ This is the most comprehensive survey of the
clinical status of patients carrying a 1–3 D4Z4
reduced allele (DRA). Data were acquired
through the Italian National Registry for faciosca-
pulohumeral muscular dystrophy (FSHD) (INRF),
which systematically collects clinical and
molecular data from the whole Italian territory.
▪ The Infantile Anamnestic Questionnaire (IAQ)
form was designed to acquire retrospective infor-
mation about pregnancy, delivery, birth and peri-
natal period of carriers of 1–3 DRA.
▪ Mixed methods were used to obtain a standar-
dised clinical assessment of all participants,
including questionnaire, interview data and a
structured medical assessment undertaken by
the Italian Clinical Network for FSHD (ICNF).
▪ Data were usually self-reported for the medical
history, without access being sought to indivi-
duals’ health records.
▪ The data sets were derived only from Italy and
have their own limitations.
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estimated prevalence of 1:20 000.1 FSHD is considered an
autosomal dominant disorder, with a typical onset within
the second decade of life.2 3 The disease presents a
remarkably wide variety of phenotypic expressions,
ranging from almost asymptomatic subjects to severe
wheelchair-dependent patients.4–6 The classical FSHD
phenotype, ﬁrst described as an independent nosological
entity in 1884, by Landouzy and Dejerine,7 is characterised
by progressive facial, shoulder girdle and pectoral muscle
weakness and atrophy. Disease progression may lead to
involvement of abdominal and pelvic muscles, causing
lumbar hyperlordosis and a waddling gait. Weakness of
anterior leg muscles results in a steppage gait.
Several genotype–phenotype correlation studies
reported a rough inverse correlation between the
number of D4Z4 repeats and the severity of FSHD.5 8–10
It has thus been suggested that alleles of extremely short
size (1–3 D4Z4 repeats) are associated with the most
severe form of disease.5 6 8 11 A number of reports
described cases carrying very short D4Z4 alleles with 1–3
D4Z4 repeats characterised by childhood onset, rapid
progression of muscle weakness and extra-muscular clin-
ical features.12–20 In 1994, Brouwer et al21 introduced the
concept of Infantile Onset FSHD, based on the follow-
ing diagnostic criteria: (1) signs or symptoms of facial
weakness by 5 years of age; (2) signs or symptoms of
scapular girdle weakness by 10 years of age.
However, several exceptions to these general trends
have been found since the molecular analysis of the
D4Z4 region became part of clinical diagnoses.
Differences of clinical expression have been documen-
ted between participants carrying shorter alleles, varying
from very severe forms of disease and complex pheno-
types starting in infancy,12–20 to milder form or asymp-
tomatic carriers.6 22–25 Based on the results presented in
these studies, it was not possible to establish whether a
congenital form of FSHD exists and whether detection
of a 1–3 D4Z4 reduced allele (DRA) is always predictive
of a severe phenotype with infantile onset. Furthermore,
it is unclear whether additional clinical features
observed in some patients with FSHD represent the
extreme of the FSHD clinical spectrum or if they result
from random associations.
In the present study, we investigated the prognostic sig-
niﬁcance of very short 4q35 alleles (1–3 DRA), through
the clinical evaluation of 66 index cases and 33 relatives.
Moreover, we searched for signs of perinatal onset
through the systematic collection of anamnestic records
of 80 patients carrying 1–3 DRA. Our study aimed to
examine the clinical variability in the cohort of the parti-
cipants carrying the shortest 4q35 alleles, presented in
earlier clinical studies,6 26–28 supporting the hypothesis
that additional factors must contribute to FSHD disease.
METHODS
Study design and subject selection
The study was performed on FSHD families accrued
through the Italian Clinical Network for FSHD (ICNF)
(http://www.fshd.it).29 The INCF is distributed across all
of Italy, and includes a diagnostic laboratory at the
University of Modena and Reggio Emilia, and 14 clinical
centres, networking with the Italian Association of
Myology (http://www.miologia.org). All clinical and
molecular data were collected in the Italian National
Registry for FSHD (INRF) database at the Miogen
Laboratory at the University of Modena. The present
study was conducted from January 2008 to December
2013. Of 850 index cases from the INRF, we identiﬁed
114 index cases carrying DRA with 1–3 repeats
(ﬁgure 1A) and fulﬁlling the clinical diagnostic criteria
deﬁned for FSHD.30 Family studies were conducted in
66 index cases, in which clinical and molecular analysis
was extended to all available relatives willing to partici-
pate. Screening for 1–3 DRA was performed in 226 rela-
tives. We deﬁned de novo cases as single participant with
neither parent carrying DRA; when the DRA was
detected in one of the parents and/or other family
members (ie, sibs), we classiﬁed the participant as famil-
ial. We considered participants as not informative when
it was not possible to examine their parents and/or
other informative family members.
Informed consent, according to the Declaration of
Helsinki, was obtained from each participant enrolled in
the study.
Clinical examination
The clinical examination was performed using the stan-
dardised FSHD clinical protocol with validated inter-
rater reliability.29 The FSHD clinical protocol was devel-
oped by the ICNF in order to numerically deﬁne the
clinical severity of the motor impairment. The FSHD
score, which translates disability into a number, ranges
from zero, when no objective evidence of muscle func-
tional impairment is present, to 15, when all the muscle
groups tested are severely impaired (http://www.fshd.it).
Age at onset was estimated on the basis of patients’
records. To obtain a more objective evaluation of facial
weakness onset, we asked speciﬁc questions, such as,
‘Have your relatives ever noticed that you were sleeping
with half-closed eyes?’; ‘Have you ever been able to
drink with a straw?’; ‘Have you ever noticed difﬁculty in
blowing out candles?’ (see online supplementary
ﬁgure S1). When participants did not report of motor
impairment, but a mild muscle weakness was observed
during clinical examination, we arbitrarily considered
the age at examination as the age at onset, according to
previous reports.6 31
Data about age at onset were available for all index
cases, while the clinical re-evaluation using FSHD clin-
ical score was performed in the 61 index cases and 33
relatives recruited for the family study (ﬁgure 1A,B).
In order to investigate the earliest signs of disease and
to rule out pre- or perinatal events as possible causes of
delayed achieving of motor milestones, we designed the
Infantile Anamnestic Questionnaire (IAQ) (see online
supplementary ﬁgure S1). All data about: (1) pregnancy,
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(2) birth, (3) the prenatal period and ﬁrst month of life
and (4) psychomotor and language development were
collected in a retrospective manner. Items related to
each section were scored as normal/altered. We col-
lected anamnestic reports about neurological examina-
tions in the ﬁrst year of life, together with clinical and
instrumental data in the following years, whenever pos-
sible, in 80 cases carrying 1–3 DRA (ﬁgure 1B).
Molecular characterisation
DNA was prepared from isolated lymphocytes according
to standard procedures. In brief, restriction endonucle-
ase digestion of DNA was performed in agarose plugs
with the appropriate restriction enzyme: EcoRI, EcoRI/
BlnI. Digested DNA was separated by pulsed ﬁeld gel
electrophoresis (PFGE) in 1% agarose gels, as previously
described.28
Allele sizes were estimated by Southern hybridisation
with probe p13E-11 of 7 μg of EcoRI-digested, EcoRI/
BlnI-digested genomic DNA extracted from peripheral
blood lymphocytes, electrophoresed in a 0.4% agarose
gel, for 45–48 h at 35 V, alongside an 8–48 kb marker
(Bio-Rad) (see online supplementary ﬁgure S2A).
Participants carrying alleles of 11–19 kb (1–3 D4Z4
units) in size were included in the study (see online
supplementary ﬁgure S2B). To distinguish whether the
DRA came from chromosome 10q or from 4q, DNA
from each proband was analysed by NotI digestion and
hybridisation with the B31 probe, to conﬁrm the
chromosome 4q origin of the 11–19 kb EcoRI allele.28
Restriction fragments were detected by autoradiog-
raphy or by using a Typhoon Trio system (GE
Healthcare).
Statistical analysis
Comparison of age at onset was performed in de novo,
familial and relatives of index cases using the non-
parametric Wilcoxon rank-sum (for comparison between
two groups) or Kruskal-Wallis (for comparison among
three groups) test. To calculate the prevalence of infantile
onset, we subdivided the patients on the basis of the age
at onset, before 10 years and after 10 years of age. The
prevalence of infantile onset was then compared across de
novo, familial and relatives of index cases using χ2 test.
Comparison of the FSHD score among de novo, familial
and relatives of index cases was performed using a general
linear model adjusted by sex and age at examination.
Wald tests were used to evaluate if FSHD score differs
between de novo, familial and relatives of index cases.
For the cohorts of probands and family members, time
before developing disease was estimated from birth to the
earliest age at onset of motor impairment. Kaplan-Meier
survival analysis was used to estimate the age-speciﬁc cumu-
lative motor impairment risk and loss of independent
walking,32 with the corresponding 95% CI. The differences
in cumulative risk between de novo and familial index cases,
carriers of 1–3 DRA, were evaluated using the Log rank test.
RESULTS
High percentage of de novo rearrangements among
carriers of 1–3 DRA
Molecular analysis of 114 index cases from the INRF
revealed that four participants were carriers of a somatic
mosaicism for DRA. Forty-four cases were considered as
not informative, since parents and/or other family
members were not available for the molecular
Figure 1 Selection of probands
from the Italian National Registry
of facioscapulohumeral muscular
dystrophy (FSHD) for clinical and
molecular study. (A) Data on age
at onset were available for all
index cases carrying 1–3 D4Z4
reduced alleles (DRA); FSHD
clinical score was assessed in 61
index cases and 33 relatives
carrying 1–3 DRA, recruited for
the family study. (B) The Infantile
Anamnestic Questionnaire was
administered in 80 cases carrying
1–3 DRA.
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investigation. In 66 unrelated index cases, we extended
molecular characterisation to parents and/or other rela-
tives and found that 26 probands were familial (39.4%)
and 40 probands were de novo (60.6%). We also estab-
lished the parental origin of de novo rearrangements in
31 cases and found that 48.4% were from the father and
52.6% were from the mother. Parental age at conception
ranged from 18 to 43 years (maternal mean age at con-
ception: 28.1±5.1 years; paternal mean age at concep-
tion: 31.3±5.3). In neither de novo cases nor in familial
cases did we observe any correlation between the detec-
tion of a de novo D4Z4 rearrangement at 4q with the
parent’s age at conception.
Our analysis shows that the percentage of de novo
cases in our cohort is higher (60.6%) than that previ-
ously described in the whole FSHD1 population
(10–30%).9 10 33–37 However, when we considered the
246 probands with 4–8 DRA we found that only 14 cases
carried a de novo DRA (5.7%). Therefore, the overall
percentage of de novo cases (17.3%) observed in the
Italian cohort of 312 FSHD1 probands does not differ
from published records. Instead, our analysis shows a
skewed percentage of carriers of de novo rearrangement
in the cohort of 1–3 DRA carriers, rather than in the
cohort of 4–8 DRA carriers.
FSHD onset before 10 years of age is more prevalent
among de novo carriers
Several studies suggest that carriers of 1–3 DRA develop
a severe form of disease. In particular, the age at onset
has been considered the clinical feature discriminating
different FSHD phenotypic entities,21 and has been used
as a prognostic parameter for deﬁning phenotype sever-
ity.31 In a previous study, we found that FSHD occurs
earlier in families in which 1–3 DRA segregate.6 In the
present study, we extended our analysis to all probands
carrying 1–3 DRA, subdivided in two groups, de novo
and familial. Table 1A shows that the mean age at onset
observed among de novo probands appears signiﬁcantly
earlier than in familial.
To verify the prevalence of infantile onset, we then sub-
divided these two groups of patients on the basis of the
age at onset, before 10 years and after 10 years of age
(table 1B). In 54.5% of index cases carrying 1–3 DRA,
the disease onset was in the ﬁrst decade of life. A higher
percentage of these cases with infantile onset reported
facial weakness as the most common sign of disease
(76.5%), while shoulder girdle weakness at onset resulted
most commonly (69%) among patients developing FSHD
after 10 years of age. Notably, the majority of patients
with early disease onset were de novo. In contrast, the
majority of patients with disease onset after 10 years of
age were familial. We then estimated the age-speciﬁc
cumulative motor impairment incidence (see online sup-
plementary ﬁgure S3A), with the corresponding 95% CI
in the two cohorts of de novo and familial probands by
Kaplan-Meier survival analysis. For each individual, we
assessed the interval of time from birth to the earliest age
at onset of motor impairment. Supplementary ﬁgure S3A
shows that, among participants carrying a de novo 1–3
DRA, the risk of developing motor impairment is 65% by
age 10 years, 88% by age 15 years and 98% by age
20 years. Among participants carrying a familial 1–3 DRA
the risk is 38% by age 10 years, 77% by age 15 years and
88% by age 20 years. Therefore the risk of developing
FSHD before 10 years of age is signiﬁcantly higher in par-
ticipants carrying a de novo 1–3 DRA.
In our previous work6 on the large cohort of FSHD1
families, we showed that the risk of developing motor
impairment is higher in male probands/relatives during
adulthood (18–55 years), and is similar between males
and females in childhood-teens and in the elderly. In
this cohort of patients carrying 1–3 DRA, the cumulative
risk of motor impairment according to sex did not show
Table 1 Age at onset among de novo and familial index cases carrying 1–3 DRA
(A)
Mean age at onset
1–3 DRA index cases Number of participants Years SD p Value*
De novo 40 8.1 6.0
Familial 26 13.1 10.1 0.020
Total 66
(B)
Age at onset
0–10 years >10 years
1–3 DRA
index cases
Number of
participants
Number of
participants Per cent
Number of
participants Per cent p Value†
De novo 40 26 65.5 14 35.5
Familial 26 10 38.5 16 61.5 0.045
Total 66 36 30
*Wilcoxon rank-sum test p value.
†χ2 Test p value.
DRA, D4Z4 reduced allele.
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signiﬁcant difference among males and females (log
rank test p value=0.305). We hypothesise that the
absence of gender difference is due to the fact that, in
this group, the disease onset occurs, on average, before
patients reach 20 years of age.
Infantile onset does not always predict a very severe
clinical outcome
It has been reported that extremely short 4q35 alleles
(1–3 D4Z4 units) are associated with more severe forms
of FSHD.5 6 8 11 Considering the earlier average onset in
de novo cases compared to familial 1–3 DRA carriers, we
tested whether de novo index cases present a more
severe disease expression, comparing the degrees of
motor disability indicated by the FSHD score.29
Statistical evaluation failed to detect any signiﬁcant dif-
ference in the mean FSHD score adjusted by age and
sex between the two groups (10.6 in de novo index cases
vs 9.5 in familial index cases; 95% CI, respectively, (8.0
to 11.3), (9.3 to 12.0); Wald test p value=0.280).
We then calculated the age-speciﬁc relative risk of loss
of independent walking ability in de novo familial index
cases, using Kaplan-Meier statistics. This analysis did not
detect a statistically signiﬁcant difference between the
two groups (see online supplementary ﬁgure S3B),
although the percentage of wheelchair-bound patients
under 40 years of age is higher in de novo index cases
(70%) versus familial index cases (35%). Finally, com-
parison of the severity of disease expression between
index cases (both de novo and familial) with early age at
onset (0–10 years; age and sex adjusted mean FSHD
score=11.4) versus probands with age at onset over
10 years (age and sex adjusted mean FSHD score=9.5)
failed to detect statistically signiﬁcant more severe FSHD
disease in probands with infantile onset (Wald test p
value=0.064). Overall, the lack of signiﬁcant differences
in each of these three comparisons argues against the
idea that early FSHD onset is necessarily associated with
a more disabling outcome.
Relatives carrying 1–3 DRA are not always severely
affected
In eight families, we were able to extend molecular ana-
lysis to three generations, and found that the molecular
defect appeared de novo and was transmitted to off-
spring in six members. Three carriers of de novo muta-
tion were probands, whereas three other carriers were
discovered because of the appearance of FSHD in one
child. Importantly, two of them were unaffected (see
online supplementary ﬁgure S4) at the time of examin-
ation (41 and 45 years, respectively) and one suffered
from a mild form of disease (FSHD score 3 at 38 years
of age). These observations indicate that the presence of
a de novo 1–3 DRA does not always associate with a
severe phenotype.
We compared the age at disease onset detected in the
group of familial probands with that recorded in the
group of 33 relatives carrying a DRA. This comparison
displayed that affected relatives had signiﬁcantly later
onset of FSHD than the probands (table 2A).
We also compared the degree of motor impairment,
recorded as FSHD score, detected in the two groups.
The age and sex adjusted mean FSHD score received by
relatives was signiﬁcantly lower than that recorded in the
probands (4.7 vs 9.5; Wald test p value <0.0001).
Notably, four relatives (12.1%), respectively aged 33,
42, 47 and 50 years, presented no muscle weakness
(table 2B). Overall, similarly to what we observed among
carriers of 4–8 DRA,6 we found a reduced severity of
clinical expression also in the group of relatives carrying
very short D4Z4 allele in comparison with probands,
including participants with no signs of disease after the
age of 40 years.
Carriers of 1–3 DRA did not show signs of prenatal and
neonatal FSHD onset
To systematically obtain information about the perinatal
period and the appearance of the ﬁrst signs and/or
symptoms of disease, we designed the IAQ (see online
Table 2 Age at onset in familial index cases and their relatives carrying 1–3 DRA
(A)
Mean age at onset
1–3 DRA carriers Number of participants Years SD p Value*
Probands 26 13.1 10.1
Relatives 29 17.1 14.2 0.019
Total 55
(B)
Age at onset
0–10 years >10 years Unaffected
1–3 DRA index
cases
Number of
participants
Number of
participants Per cent
Number of
participants Per cent
Number of
participants Per cent
Probands 26 12 38.5 14 61.5 0 0.0
Relatives 33 13 39.4 16 48.5 4 12.1
*Wilcoxon rank-sum test p value.
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supplementary ﬁgure S1). We gathered anamnestic data
about pregnancy, delivery and birth from all participants
who were able to respond to this questionnaire. We
interviewed 80 cases carrying 1–3 DRA (ﬁgure 2).
Figure 2 shows that no signiﬁcant alterations in preg-
nancy, delivery and birth were reported. There was no
report of any ﬂoppy infant at birth. In 72 of 80 partici-
pants (90%), psychomotor development milestones were
reached appropriately.
This analysis shows that children carrying 1–3 DRA do
not display signs of muscle weakness prenatally or at
birth. Moreover, signs that can possibly be attributed to
early onset of muscle weakness are reported only in a
small percentage of participants. Therefore we conclude
that very early onset is not a frequent feature of FSHD.
Carriers of 1–3 DRA with extra-muscular clinical
conditions
In some reports, severe FSHD is associated with extra-
muscular features such as sensorineural deafness, Coats’
retinopathy, epilepsy and mental retardation. We
assessed the frequency of additional clinical conditions
in the cohort of 61 index cases carrying 1–3 DRA, sum-
marised in ﬁgure 3.
Thirteen participants suffered from sensorineural
deafness (21.3%). In eight cases, it was isolated, with no
other recognisable medical condition, and in ﬁve cases
we detected additional extra-muscular manifestations.
In four cases, we observed Coats’ retinopathy (6.6%).
In one it was found as an isolated condition, whereas in
three other cases it was associated with sensorineural
deafness or cognitive impairment. Cognitive impairment
was reported in six cases (9.8%), and two of these also
suffered from epilepsy. All cases with mental retardation
showed a very severe form of disease.
We also investigated the presence of restrictive respira-
tory disease requiring intervention, previously described
in about 1% of patients with FSHD1, typically in patients
with severe muscle weakness.3 In our cohort of 61 index
cases with 1–3 DRA, we identiﬁed 7 cases (11.5%) with
respiratory insufﬁciency requiring non-invasive ventila-
tion (NIV). Two of these showed a complex phenotype
with additional extra-muscular manifestations (ﬁgure 3),
while all the others suffered from a disabling form of
disease and required use of NIV since the ages of 22, 29,
30, 42 and 53 years, respectively.
DISCUSSION
Since molecular analysis of the D4Z4 region was intro-
duced to study FSHD, it has been suggested that very
severe forms of disease are associated with a very short
DRA.5 6 8 11 This notion has supported the idea that a
rough inverse correlation exists between the size of
D4Z4 allele and disease severity. Moreover, it has been
long debated whether ‘infantile FSHD’ might exist as a
distinct nosological entity, characterised by speciﬁc pecu-
liarities that distinguish it from classical FSHD with onset
in the second decade of life.21 22 ‘Infantile FSHD’ has
been deﬁned by childhood onset and severe muscle
impairment, associated with high-frequency hearing loss,
retinal vascular abnormalities, mental retardation and
epilepsy.14 15 18 20 By revising the literature, as sum-
marised in ﬁgure 4, we found that not all severe cases
had an infantile onset, and not all carried a very
reduced size D4Z4 allele. However, the different designs
used in each of these previous studies prevented the pos-
sibility of pooling various observations to obtain a com-
plete or more deﬁned picture of clinical features of
participants carrying ‘very short’ D4Z4 allele.
Here, the large number of index cases carrying DRA
with 1–3 units accrued through the INRF allowed us to
obtain more precise information about this group of
patients. In particular, we aimed at verifying whether
perinatal onset of FSHD exists and whether presence of
a 1–3 DRA is always predictive of a severe phenotype
associated with infantile onset. In addition, we searched
Figure 2 Infantile anamnestic
records of 80 carriers of 1–3
D4Z4 reduced alleles (DRA) (NA,
not applicable).
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this cohort of patients for the presence of additional
clinical conditions determining complex phenotypes.
First, our analyses showed that the majority of 1–3
DRA carriers (60.6%) are de novo. These data,
together with the observation that 1–3 DRAs have
never been detected in the normal population,28
support the notion that the D4Z4 repeat array is
highly recombinogenic and therefore prone to a high
mutation rate.35 37
Second, the majority (72.2%) of cases presenting
disease onset before 10 years of age are isolated and
carry a de novo rearranged DRA; in contrast, the
majority (53.3%) of familial FSHD1 cases develop
around the second decade of life (table 1B). However,
we did not ﬁnd a statistically signiﬁcant difference in
disease outcome between de novo and familial pro-
bands, even though there is a trend towards a more
severe progression among de novo cases (age and sex
adjusted mean FSHD score in de novo vs familial pro-
bands, is 10.6 vs 9.5). We conﬁrm a more severe
phenotype in index cases carrying 1–3 DRA in com-
parison with participants carrying longer alleles (4–10
DRA).6 38 Our data also conﬁrmed that, among index
cases with infantile onset, the majority (76.5%)
reported facial weakness as the ﬁrst sign of disease,
presenting difﬁculty in closing eyes and pufﬁng cheeks,
or progressive facial hypomimia. In three participants,
we collected anamnestic records of abnormalities in
pronouncing some phonemes at the age of 3–4 years,
and interpreted these difﬁculties as possibly due to the
onset of facial muscle weakness. Two cases were initially
misdiagnosed as affected by Moebius syndrome, most
likely because of the very early onset of severe facial
muscle weakness. Instead index cases with FSHD onset
after 10 years reported shoulder girdle weakness as the
most common ﬁrst sign of the disease, according to
the previous reports.6 39 40
Third, even when signs or symptoms of muscle weak-
ness are detected within the ﬁrst year of life, the long-
term disease outcome does not differ from cases with
later onset.
Fourth, the use of the IAQ conﬁrmed that pre- and
perinatal onset is not present in the group of 1–3 DRA
carriers.
Figure 3 Clinical features of 1–3 D4Z4 reduced alleles (DRA) carriers with extra-muscular comorbidities (FSHD,
facioscapulohumeral muscular dystrophy; M, male; F, female).
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Fifth, among the 33 relatives carrying 1–3 D4Z4 alleles,
4 (12.1%) were unaffected, conﬁrming the incomplete
penetrance also in the cohort of participants carrying
shorter DRA.6 Moreover, relatives displayed a milder
phenotype than family proband, supporting the notion
that in this subgroup of patients, the genetic background
also plays a role in modulating the disease expression.6
Finally, in contrast with the previous reports,11–19 our
investigations demonstrated that only seven cases
(11.5%; 5 de novo and 2 familial) displayed extra-
muscular comorbidities (Coats’ retinopathy, sensori-
neural deafness, mental retardation, epilepsy) in various
combinations (ﬁgure 4). We thus conclude that extra-
muscular clinical features are not part of a speciﬁc noso-
logical entity associated with 1–3 DRA.
In summary, our study shows that a high variability of
FSHD clinical expression is also present among partici-
pants carrying 1–3 DRA, with some healthy relatives car-
rying the same DRA as the affected ones. The
observation that the majority of 1–3 DRA cases carry ‘de
novo’ rearrangements, conﬁrms the high frequency of
recombination events within the D4Z4 region.
Importantly, our comparisons of probands and relatives
disclose that the presence of a de novo 1–3 DRA is not
always associated with a disease phenotype, and empha-
sises the possibility that a more disabling phenotype
might have a negative inﬂuence on reproductive ﬁtness.
Accordingly, in our cohort de novo rearrangements in
unaffected individuals or in patients displaying mild phe-
notypes had normal reproductive ﬁtness with transmis-
sion of the DRA to the offspring.
Our analysis, conducted on the largest cohort of 1–3
DRA carriers to date, shows that 1–3 DRAs are not
always predictive of infantile onset or severe disease
outcome. Importantly, the ﬁnding that only 27.9% of
1–3 DRA carriers present extra-muscular clinical condi-
tions supports the notion that additional defects contrib-
ute to a more complex clinical phenotype.
Overall, our study indicated that an important future
goal of FSHD clinical research is the selection of
patients with homogeneous clinical features, regardless
of the size of D4Z4 alleles, to provide the appropriate
background for molecular studies aimed at dissecting
the complex pathogenesis of this disease.
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